Caregen Co.Ltd

Caregen Co.Ltd

214370 · KQ · Healthcare / Pharmaceuticals

28,150.00KRW-100.00 (-0.35%)

Price History

Full chart

Market Stats

Previous Close28,250.00
Open28,500.00
Day Range27,850.00 – 29,800.00
52-Week Range39,300.00 – 153,323.84
Volume68.66K
Market Cap2.10T
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.05%
Beta0.18
50-Day Avg50,752.00
200-Day Avg81,655.50

About

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names. The company's products are used in anti-aging, anti-pigmentation, anti-hair loss, anti-inflammation, and other skin troubles, as well as blood sugar control, baby skin care, and acute muscle pain applications. In addition, its products in pipeline include pharmaceuticals in the areas of wet and dry macular degeneration, diabetic retinopathy, cataract, hyperhidrosis, pain relief, obesity, psoriasis, scar, arthritis, rhinitis, anti-virus, and Covid-19 treatment; and medical devices for face beauty treatment, scalp and hair improvement, body care, arthritis, and new face beauty treatment. Further, the company is developing cosmeceutical produts for anti-wrinkle, whitening, sun block, atopic dermatitis care, particulate matter inhibition, double chin removal, dark circle care, reduction of cellulite, sebum secretion control, and pore tightening applications; and food supplements in the areas of hangover cure, cholesterol control, and body fat lipolysis. Caregen Co., Ltd. was founded in 2001 and is based in Anyang-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEOMr. Yongji Chung Ph.D.
  • Employees157
  • HeadquartersCaregen Building, Anyang-Si, South Korea, 14119, Korea
  • Websitehttp://caregen.co.kr

Leadership

  • Mr. Yongji Chung Ph.D.Chief Exec. Officer and Chief Technology Officer · b. 1970
  • Ms. Hui-Suk RaDirector · b. 1973

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue36.42B46.84B57.89B51.21B64.70B60.30B59.09B69.10B79.21B82.59B72.81B
Growth (%)-+28.62%+23.58%-11.53%+26.34%-6.81%-2.00%+16.94%+14.63%+4.26%-11.84%
Cost of Revenue6.49B8.14B11.94B18.36B11.00B11.65B13.55B16.75B20.85B27.27B20.57B
Gross Profit29.93B38.70B45.94B32.85B53.70B48.64B45.54B52.35B58.36B55.32B52.24B
Gross Margin82.17%82.62%79.37%64.15%82.99%80.68%77.07%75.76%73.68%66.98%71.75%
Operating Expense9.39B13.02B14.37B16.30B18.55B16.67B17.26B18.72B17.99B20.72B31.84B
Operating Income20.54B25.68B31.58B16.55B35.15B31.98B28.27B33.63B40.38B34.60B20.40B
Operating Margin56.39%54.82%54.55%32.32%54.33%53.04%47.85%48.66%50.98%41.89%28.02%
EBITDA-------37.08B45.36B39.41B25.42B
EBITDA Margin-------53.66%57.27%47.72%34.91%
Net Income19.25B22.96B24.29B16.49B28.07B31.48B25.32B27.27B39.93B32.31B20.10B
Net Income Margin52.86%49.02%41.96%32.20%43.39%52.21%42.85%39.46%50.41%39.13%27.60%
R&D2.24B3.21B3.01B--3.84B5.03B6.28B5.82B7.01B5.76B
R&D as % of Total Revenue6.14%6.85%5.20%--6.37%8.51%9.10%7.35%8.49%7.91%
Interest Expense000004.44M0----
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.01%0.00%----

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets256.52B249.13B247.02B218.94B231.85B216.56B226.76B234.07B247.28B240.70B231.27B
Total Liabilities7.65B15.02B15.19B14.18B14.84B11.40B17.04B18.09B19.98B17.72B18.80B
Total Equity248.87B234.11B231.83B204.75B217.01B205.16B209.72B215.98B227.30B222.98B212.47B
Cash116.96B11.17M70-150-400-403.38M3.51M10.95M5.07B8.86B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.57B-15.94B47.88B-6.82B69.66B30.78B51.86B-27.68B28.60B13.49B18.59B
Investing Cash Flow-77.41B2.70B-40.41B-3.00B-50.87B6.92B-25.11B34.59B26.11B-4.01B-
Financing Cash Flow172.73B-35.33B-23.33B-24.35B-14.26B-43.32B-20.47B-23.85B-28.32B-36.35B-
Capital Expenditure14.92B4.32B5.57B2.28B6.16B21.08B3.89B3.03B9.70B66.97B4.92B
Free Cash Flow----13.47B8.96B46.59B-30.71B18.90B-53.49B13.67B
Dividends Paid6.43B6.43B16.42B12.28B34.74B34.74B20.59B24.51B28.50B31.45B31.13B
FCF to OCF----19.34%29.10%89.84%110.95%66.09%-396.58%73.52%
Dividend Paid to FCF----257.92%387.90%44.20%-79.84%150.76%-58.79%227.77%

Earnings

Report DateMay 4, 2016Aug 9, 2016Nov 22, 2016Feb 8, 2017May 30, 2017Aug 28, 2017Nov 28, 2017Feb 8, 2018May 14, 2018Aug 14, 2018Nov 13, 2018Mar 18, 2019May 14, 2019Aug 14, 2019Nov 14, 2019Feb 26, 2020Apr 6, 2020Jul 27, 2020Nov 4, 2020Feb 9, 2021May 12, 2021Aug 11, 2021Nov 10, 2021Feb 10, 2022May 9, 2022Aug 9, 2022Nov 7, 2022Feb 7, 2023May 4, 2023Aug 9, 2023Nov 10, 2023Mar 19, 2024May 10, 2024Aug 2, 2024Nov 8, 2024Feb 10, 2025May 9, 2025Jul 31, 2025Nov 10, 2025Mar 17, 2026May 8, 2026Aug 18, 2026
EPS Estimate---632.7573.99142.5380.78761.7695.80192.35108.12120.50------------------------------
EPS Actual337.46812.50109.10972.4033.20205.55100.80696.00112.80212.8095.60135.00518.00552.89281.00290.681453.42733.00662.001096.54783.58678.70669.13450.53767.74765.92639.86605.131439.69756.97199.46173.89193.79122.68238.11103.68172.5098.11207.80-67.15239.3088.08
Surprise---53.68%-55.13%44.22%24.78%-8.63%17.75%10.63%-11.58%12.03%------------------------------
TimingPre-marketAfter-hoursPre-marketAfter-hours-After-hoursAfter-hours-After-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-marketAfter-hoursAfter-hoursAfter-hours---Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap2.10T
Enterprise Value1.93T
Trailing P/E0.00
Forward P/E0.00
Price / Sales26.22
Price / Book8.98
Revenue (TTM)64.99B
Gross Profit (TTM)45.44B
EBITDA32.88B
Profit Margin39.61%
Operating Margin46.33%
Return on Equity1455.86%
Return on Assets8.45%
Shares Outstanding10.74M
Shares Float2.94M
Beta0.18
Dividend Yield2.05%
Dividend Rate0.00
Payout Ratio85.47%

Dividends

20261×
200.00Jun 29, 2026
20252×
200.00Dec 29, 2025237.00Jun 27, 2025
20242×
400.00Dec 27, 2024240.00Jun 27, 2024
20232×
400.00Dec 27, 2023240.00Jun 29, 2023
20222×
340.00Dec 28, 2022200.00Jun 29, 2022
20212×
300.00Dec 29, 2021160.00Jun 29, 2021
20202×
260.00Dec 29, 2020140.00Jun 29, 2020
20191×
560.00Dec 27, 2019
20181×
120.00Jun 28, 2018
20172×
120.00Dec 27, 2017120.00Jun 29, 2017
20162×
200.00Dec 28, 2016600.00Jun 29, 2016
20151×
120.00Dec 29, 2015

Stock Splits

  • Aug 25, 20235:1